ASCO甲状腺癌全身治疗指南
推荐覆盖分化型、分化型高级别或低分化型、未分化型和髓样甲状腺癌患者的全身治疗使用。
要点
- 推荐覆盖分化型、高级别分化型或低分化型、未分化型及髓样甲状腺癌的全身治疗。
- 专家组基于现有证据和非正式共识形成循证推荐。
核心结论
- ASCO发布甲状腺癌全身治疗循证推荐,覆盖分化型、高级别分化型或低分化型、未分化型和髓样甲状腺癌。
主要发现
- 共66篇出版物构成该指南的证据基础。
- 关注结局包括总生存期、无病生存期和安全性。
关键数值与推荐
- 推荐涉及分化型、高级别分化型或低分化型、未分化型和髓样甲状腺癌患者的全身治疗使用。
临床怎么用
- 临床医生可参考该循证推荐,结合独立专业判断,用于甲状腺癌患者的全身治疗决策。
局限性
- 指南为自愿使用,不构成综合或确定的治疗选择,不适用于所有患者、干预、疾病或疾病阶段。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual. ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines.Clinical Practice Guidelines and other guidance ("Guidance") provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more. PURPOSE: To provide evidence-based recommendations on the use of systemic therapy in different types of thyroid cancers. METHODS: The American Society of Clinical Oncology convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. The literature search included studies published between January 1, 2000, and November 5, 2025, and comprised systematic reviews, meta-analyses, randomized controlled trials, and observational studies. Outcomes of interest included overall survival, disease-free survival, and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: A total of 66 publications were identified to inform the evidence base for this guideline. RECOMMENDATIONS: Evidence-based recommendations address the use of systemic therapy in patients with well-differentiated, differentiated high-grade or poorly differentiated, anaplastic, and medullary thyroid cancer.Additional information is available at https://ascopubs.org/topics/asco-guidelines/head-neck-cancer.
引用
- Saba NF, Ismaila N, Adkins D, et al. Systemic Treatment of Thyroid Cancer: ASCO Guideline. J Clin Oncol. 2026. PMID: 41921121. doi:10.1200/JCO-26-00235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。